abatacept and treatment Archives - ACR Meeting Abstracts

Abstract Number: 2414 • ACR/ARP Annual Meeting 2019
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial
Jolien van Nimwegen¹, Esther Mossel ¹, Robin Wijnsma ¹, Greetje van Zuiden ¹, Konstantina Delli ¹, Alja Stel ¹, Bert van der vegt ¹, Erlin Haacke ¹, Lisette Olie ¹, Leonie Los ¹, Gwenny Verstappen ¹, Sarah Pringle ¹, Fred Spijkervet ¹, Frans Kroese ¹, Arjan Vissink ¹, Suzanne Arends ² and Hendrika Bootsma ³, ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. The Abatacept Sjögren Active Patients phase…
Abstract Number: 2040 • ACR/ARHP Annual Meeting 2013
Pilot Study Of Abatacept In Patients With Refractory Autoimmune Chronic Urticaria
Clifton O. Bingham III¹, Marilyn Towns¹ and Susan J. Bartlett², ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada
Background/Purpose: Associations between chronic urticaria (CU) with autoantibodies and other autoimmune conditions have implicated T cells in CU initiation and/or propagation. Many patients (pts) have…
Abstract Number: 522 • ACR/ARHP Annual Meeting 2013
Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study
PM Meiners¹, A Vissink², Fkl Spijkervet³, EA Haacke⁴, WH Abdulahad⁵, E Brouwer⁵, MG Huitema⁵, N Sillevis Smitt-Kamminga⁶, FGM Kroese⁷, S Arends⁵ and H Bootsma⁵, ¹Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁴Pathology, University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁶Opthalmology, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Traditional DMARDs have limited effects in primary Sjögren's (pSS) patients. B cell depletion therapy with rituximab showed efficacy, but had some side-effects. T and…

Abstracts tagged "abatacept and treatment"

Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial

Pilot Study Of Abatacept In Patients With Refractory Autoimmune Chronic Urticaria

Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study